Paper
Paper
Search...
Search ResearchHub...
Ctrl+K
New
Home
Browse
Earn
Fund
RH Journal
Notebook
Lists
Leaderboard
RSC
USD
Changelog
Terms
Privacy
Issues
Docs
Support
Foundation
About
Rituximab chimeric anti-CD20 monoclonal antibody therapy ... | ResearchHub
Paper
Paper
Search...
Search ResearchHub...
Ctrl+K
New
Home
Browse
Earn
Fund
RH Journal
Notebook
Lists
Leaderboard
RSC
USD
Changelog
Terms
Privacy
Issues
Docs
Support
Foundation
About
Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.
0
Authors
Peter McLaughlin
17 more
Peter McLaughlin
•
Antonio Grillo-López
15 more
•
B.K. Dallaire
Published
August 1, 1998
Paper
Conversation
0
Reviews
0
Bounties
0
Sign in to comment
Add a comment...
Best
Supporters
Support the authors with ResearchCoin
Tip RSC
Journal
Journal of Clinical Oncology
Topics
Medicine
Cancer Oncology
Immunology
Internal Medicine
Gastroenterology
Show all topics
DOI
10.1200/jco.1998.16.8.2825
